News

Alcami to Provide Manufacturing Services for Trevena’s Pain Management Injection

September 03, 2020

Alcami will provide services for Trevena’s OLINVYK (oliceridine) injection, an opioid approved for the management of acute pain severe enough to require an intravenous opioid analgesic in adults.

BIO Message: Keep Drug Development Independence

September 03, 2020

BIO leaders urge biopharmaceutical companies to apply scientific principles in seeking drug and vaccine approvals.

Daré Bioscience and Avomeen Partner to Advance Women’s Health Programs

September 03, 2020

Avomeen will offer contract product development laboratory services to support the advancement of Daré’s innovative pipeline of investigational products dedicated to women’s health.

Leader of the Pack?

September 02, 2020

AstraZeneca has potentially taken poll position in the race to develop a novel coronavirus vaccine, but will AZD1222 be ready in 2020?

HJB and Ansun Biopharma Partner on Biologics CMC Development and Manufacturing

September 02, 2020

The companies have entered into a strategic partnership for the CMC development and manufacturing of Ansun’s biologics pipeline.

Kohlberg and Mubadala to Acquire Majority Stake in PCI Pharma Services

September 02, 2020

The companies have signed a definitive agreement to acquire a majority stake of PCI Pharma Services.

Sanofi, Regeneron Halt Development of Kevzara as a Potential COVID-19 Treatment

September 02, 2020

The companies provided an update stating that the biologic did not meet a primary endpoint in a Phase III clinical trial when compared with placebo in the treatment of COVID-19 patients.

iBio and Planet Biotechnology Partner to Develop COVID-19 Therapeutic

September 02, 2020

The companies will collaborate on the production of a novel anti-SARS-CoV-2 immunoadhesin in iBio’s FastPharming manufacturing system.

FDA Publishes Guidance on Control of Nitrosamines

September 02, 2020

The guidance recommends steps to detect and prevent nitrosamine impurities in pharmaceutical products.

EMA Evaluating COVID-19 Treatment

September 02, 2020

The agency is reviewing an application for Dexamethasone Taw for treating adult patients with COVID-19.